NGM Biopharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	129	71	410	1,376	2,091	1,232
Market Cap Growth	-	-82.68%	-70.19%	-34.18%	69.66%	-
Enterprise Value	-21	-79	140	1,019	1,794	886
PE Ratio	-0.50	-0.50	-2.52	-11.44	-20.40	-28.80
PB Ratio	0.86	0.48	1.58	4.10	7.47	3.73
P/FCF Ratio	-0.53	-0.53	-2.80	-18.37	-24.49	-27.59
P/OCF Ratio	-0.54	-0.54	-2.84	-18.79	-25.04	-29.93
EV/EBITDA Ratio	0.57	0.57	-0.89	-9.06	-18.70	-25.18
EV/EBIT Ratio	0.55	0.55	-0.86	-8.47	-17.51	-20.70
EV/FCF Ratio	0.59	0.59	-0.96	-13.60	-21.02	-19.84
Debt / Equity Ratio	-	-	0.02	0.03	-	-
Debt / EBITDA Ratio	-	-	-0.03	-0.09	-	-
Debt / FCF Ratio	-	-	-0.04	-0.14	-	-
Quick Ratio	7.45	7.45	5.92	6.07	6.97	8.85
Current Ratio	7.79	7.79	6.04	6.18	7.24	8.94
Return on Equity (ROE)	-77.90%	-77.90%	-56.60%	-32.90%	-34.80%	-19.10%
Return on Assets (ROA)	-67.80%	-67.80%	-48.50%	-28.50%	-30.10%	-12.20%
Return on Capital (ROIC)	-104.87%	-104.87%	-83.63%	-57.37%	-68.28%	-46.23%
Earnings Yield	-110.77%	-200.38%	-39.65%	-8.74%	-4.90%	-3.47%
FCF Yield	-103.83%	-187.82%	-35.66%	-5.44%	-4.08%	-3.62%
Buyback Yield / Dilution	-3.18%	-3.18%	-3.72%	-12.57%	-36.14%	-687.90%
Total Shareholder Return	-3.18%	-3.18%	-3.72%	-12.57%	-36.14%	-687.90%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).